Results 1 to 10 of about 5,080,573 (227)

Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort. [PDF]

Hematol Oncol
ABSTRACT Although clinical trials showed outcomes improvement in MCL, their applicability to real‐world practice remains limited. Using the prospective REALYSA registry (NCT03869619), we evaluated contemporary management, highlighting evolving practices and differences by age. Among 295 patients, 63% were ≥ 65 years, 48% had a high‐risk MIPI score with
Cheminant M, Fogarty P, Carras S, Sarkozy C, Rossi C, Fornecker L, Fontanet B, Chauchet A, Leguyader-Peyrou S, Lebras L, Oberic L, Ysebaert L, Damaj G, Labouré G, Fouillet L, Guidez S, Lemonnier F, Bouabdallah K, Gastinne T, Morineau N, Amorim S, Jardin F, Abraham J, Houot R, Thieblemont C, Morschhauser F, Gressin R, Le Gouill S, Hermine O, Cherblanc F, Monnereau A, Belot A, Ghesquieres H, Tessoulin B.   +33 more
europepmc   +2 more sources

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
ABSTRACT Bruton tyrosine kinase inhibitors (BTKis) have been employed in the treatment of mantle cell lymphoma (MCL). However, direct comparisons of ibrutinib, zanubrutinib, and acalabrutinib across treatment‐naïve (TN) and relapsed/refractory (R/R) MCL remain limited. This meta‐analysis was intended to evaluate their efficacy, addressing critical gaps
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +2 more sources

Where next for BTKi-BCL2i combinations in mantle cell lymphoma? [PDF]

Br J Haematol
Eyre TA.
europepmc   +1 more source

Proteogenomic features define subtypes of mantle cell lymphoma. [PDF]

Blood Adv
Yan Y, Chen W, Ge X, Sun J, Yu L, Garcia-Mansfield K, Zhang X, Yu Y, Xiong W, Zou D, An G, Jia Z, Pirrotte P, Li JJ, Yu Z, Hao M, Qiu L, Qi J, Wang L, Yi S.   +19 more
europepmc   +1 more source

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma. [PDF]

Curr Oncol
Puckrin R, Villa D, Fleury I, Larouche JF, Kuruvilla J.   +4 more
europepmc   +1 more source

Concurrent Mantle Cell Lymphoma and Paraneoplastic Membranous Nephropathy. [PDF]

Kidney Med
Lv D, Sun P, Li Y, Liu T, Ye F, Yu Y, Li T, Liu A.   +7 more
europepmc   +1 more source

Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma. [PDF]

Hemasphere
Albiol N, Martínez-Cibrián N, Pérez AI, Navarro-Velázquez S, Muzzi G, Oliver-Caldes A, Español-Rego M, Alserawan L, Montoro-Lorite M, Ramos C, Ayora P, Martin-López AÁ, Cabero A, Pérez-López E, García-Sancho AM, Baumann T, Sánchez-Pina JM, Chinea A, Fernández-Caldas P, Bastos-Oreiro M, Kwon M, Rodríguez-Lobato LG, Magnano L, Rivero A, Correa JG, Mozas P, Sánchez-Castañón M, Mata-Molanes JJ, Charry P, Álamo JR, Setoaín X, Rodríguez S, Olesti E, Sáez-Peñataro J, Fernández de Larrea C, Urbano-Ispizua Á, López-Guillermo A, Delgado J, González-Navarro EA, Juan M, Giné E, Ortiz-Maldonado V.   +41 more
europepmc   +1 more source

Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series. [PDF]

EJHaem
Rotter N, Raderer M, List A, Haslbauer F, Saini O, Egle A, Magnes T, Leisch M, Kaynak E, Buxhofer-Ausch V, Casadei B, Keil F, Rumpold H, Hess G, Greil R, Zinzani PL, Melchardt T.   +16 more
europepmc   +1 more source

Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma. [PDF]

Blood Neoplasia
Zhong W, Hojjat-Farsangi M, Barde S, Kokhaei P, Hansson L, Palma M, Zhong W, Österborg A, Moshfegh A.   +8 more
europepmc   +1 more source

Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models. [PDF]

Biomark Res
Singh S, Wang Y, Sircar A, Jindal U, Srour N, La Ferlita A, Distefano R, Soni A, Kumar D, Peralta-Camacho GJ, Zhao SL, Jafari H, Holter JC, Tinapple JW, Barlage JM, Kumar R, Berger M, Rahman K, Nezati R, Nath UK, Chaudhary N, Ranganathan P, Muthusamy N, Amador V, Li PK, Parekh S, Paik J, Baiocchi R, Song JW, Alinari L, Peterson BR, Epperla N, Jain N, Sehgal L.   +33 more
europepmc   +1 more source